Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919464 | 0.71 | — | — | |
| SCHEMBL4929669 | 0.69 | ALDH1A1 (0.34) | — | |
| SCHEMBL17275442 | 0.64 | NOS2 (0.38) | NOS2ELANE | |
| SCHEMBL3812935 | 0.64 | PTGS2 (0.34) | — | |
| SCHEMBL1763631 | 0.60 | ELANE (0.30) | ELANE | |
| SCHEMBL196325 | 0.56 | — | — | |
| Dealkylated Diethylpropion SCHEMBL25176894 | 0.55 | TDP1 (0.52) | ELANE | |
| Cathinone SCHEMBL34513 | 0.55 | TDP1 (0.52) | ELANE | |
| Dealkylated Diethylpropion SCHEMBL1050427 | 0.55 | TDP1 (0.52) | ELANE | |
| Dealkylated Diethylpropion SCHEMBL2236790 | 0.55 | TDP1 (0.52) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730911-B2 | Backbone-cyclized peptidomimetics with GLP-1R modulating activity | UNIVERSITAT ZURICH (CH) | 2020-08-04 | — | — | US | claimed |
| US-20180072774-A1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS WITH GLP-1R MODULATING ACTIVITY | POLYPHOR AG (CH) | 2018-03-15 | — | — | US | claimed |
| EP-3280723-A1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS | Polyphor AG (CH) | 2018-02-14 | — | — | EP | claimed |
| EP-2764010-B9 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| WO-2016162127-A1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2016-10-13 | — | — | WO | claimed |
| EP-2764010-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | POLYPHOR AG (CH) | 2016-03-16 | — | — | EP | claimed |
| US-20140287986-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | POLYPHOR AG (CH) | 2014-09-25 | — | — | US | claimed |
| EP-2764010-A1 | TEMPLATE -FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | Polyphor Ag (CH) | 2014-08-13 | — | — | EP | claimed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | claimed |
| WO-2013050346-A1 | TEMPLATE -FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | POLYPHOR AG (CH) | 2013-04-11 | — | — | WO | claimed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | claimed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | claimed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | claimed |
| EP-3280723-B1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| US-10730911-B2 | Backbone-cyclized peptidomimetics with GLP-1R modulating activity | UNIVERSITAT ZURICH (CH) | 2020-08-04 | — | — | US | disclosed |
| US-9957297-B2 | Template-fixed peptidomimetics as inhibitors of FPR1 | POLYPHOR AG (CH) | 2018-05-01 | — | — | US | disclosed |
| WO-2013050346-A1 | TEMPLATE -FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | POLYPHOR AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140287986-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 | FPR1, FPR3, FPR2 | NOS2 2333/4885ELANE 1388/4885 |
| US-20180072774-A1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS WITH GLP-1R MODULATING ACTIVITY | GLP1R, GIPR, SSTR1 | NOS2 1713/4885ELANE 3365/4885 |
| US-10730911-B2 | Backbone-cyclized peptidomimetics with GLP-1R modulating activity | GLP1R, GIPR, SSTR1 | NOS2 1713/4885ELANE 3365/4885 |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | NOS2 4664/4885ELANE 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.